Here's what the broker is saying about them: The first ASX 200 share that impressed is ResMed. It is a developer ... September quarter result, with 11% revenue growth translating to 35% earnings ...

ResMed Inc (NYSE:RMD) reports a robust 11% increase in net revenue year-over-year. Significant growth in Sleep and Breathing Health segment, showcasing an 11% rise in sales. Strong gross margin ...

ResMed's significant 11% year-over-year revenue growth was primarily propelled by innovations and strong demand for its sleep devices and masks. The gross margin boost was aided by manufacturing ...

Masks and Accessories Sales Growth: Increased by 11% globally. Residential Care Software Revenue: Increased by 12%. ResMed Inc (NYSE:RMD) reported a strong quarter with an 11% revenue growth ...

The company's last quarterly earnings report, which we covered last week, showed Resmed bringing home US$1.22 billion in revenues for the three months to 30 September. That was an 11% rise ...

On Friday, KeyBanc Capital Markets adjusted its outlook on ResMed (NYSE:RMD), a company specializing in medical devices for respiratory disorders, by increasing its price target.

We will see ongoing momentum. Our masks and accessories business had another strong quarter, delivering 11% year-over-year growth. The AirFit F40, ResMed's smallest oronasal mask ever, continues ...

ResMed stands to benefit from Philips’ significant product recall and the launch of its new flagship product, AirSense 11. Market share gains from Philips’ product recall may be limited as ...

Oct 24 (Reuters) - ResMed (RMD.N), opens new tab beat Wall ... The medical device maker's first quarter revenue for the fiscal year 2025 rose 11% to $1.22 billion, compared to analysts' estimates ...

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer ...